Skip to main content
Premium Trial:

Request an Annual Quote

Molecular Devices Acquisition of Axon Complete

NEW YORK, March 22 (GenomeWeb News) - Molecular Devices has completed its acquisition of Axon Instruments for a total of $132.7 million in cash and stock, the company said today.


Under the acquisition, first announced in March, Molecular Devices paid approximately $68 million in cash and issued 3.6 million shares of common stock (an approximately $64.7 million value as of July 1). Axon stockholders are receiving .00734 of a share of Molecular Devices common stock, and $0.1359 cash for each share of Axon common stock. 


Molecular Devices additionally assumed employee options to acquire about 536,000 shares of Molecular Devices common stock, as well as other options to acquire approximately 38,000 shares of Molecular Devices common stock and approximately $700,000 in cash.  The company also received about $26 million in cash that was held by Axon.


Axon, which makes instruments for electrophysiology as well as microarray scanners, is based in Union City, Calif. and has 128 employees.

The Scan

Genetic Tests Lead to Potential Prognostic Variants in Dutch Children With Dilated Cardiomyopathy

Researchers in Circulation: Genomic and Precision Medicine found that the presence of pathogenic or likely pathogenic variants was linked to increased risk of death and poorer outcomes in children with pediatric dilated cardiomyopathy.

Fragile X Syndrome Mutations Found With Comprehensive Testing Method

Researchers in Clinical Chemistry found fragile X syndrome expansions and other FMR1 mutations with ties to the intellectual disability condition using a long-range PCR and long-read sequencing approach.

Team Presents Strategy for Speedy Species Detection in Metagenomic Sequence Data

A computational approach presented in PLOS Computational Biology produced fewer false-positive species identifications in simulated and authentic metagenomic sequences.

Genetic Risk Factors for Hypertension Can Help Identify Those at Risk for Cardiovascular Disease

Genetically predicted high blood pressure risk is also associated with increased cardiovascular disease risk, a new JAMA Cardiology study says.